GREY:JUVAF - Post by User
Post by
Matteo1234on Mar 01, 2022 5:51am
240 Views
Post# 34470104
Arbitrage
ArbitrageBig boys stealing your shares in a illiquid stock. Stayhard...The news follows the Company’s identification of non-cannabinoid compound JUVA-019, on which the Company has filed a patent application and has conducted preclinical research showing that the compound is effective as a stand-alone compound in inhibiting inflammation by modulating certain biomarkers in the body. Through its research division, Juva scientists have continuously been evaluating an internally curated database of compounds found in the cannabis plant for their therapeutic benefit, leading to the identification of the two proprietary compounds: JUVA-019 and JUVA-041, which the Company has nominated as drug candidates for further pre-clinical investigation. Current efforts are focused on advancing both compounds through phenotypic models of chronic diseases of aging.